MorphoSys and GlaxoSmithKline Partner in Antibody Pact - - BioPharm International

ADVERTISEMENT

MorphoSys and GlaxoSmithKline Partner in Antibody Pact


MorphoSys has formed a global agreement with GlaxoSmithKline (GSK) to develop and commercialize MOR103, MorphoSys's proprietary HuCAL-derived antibody for treating mild to moderate rheumatoid arthritis. Under the agreement, GSK assumes responsibility for all subsequent development and commercialization of MOR103. MorphoSys receives an immediate upfront payment of EUR 22.5 million ($29.4 million) and up to EUR 423 million ($552 million), in addition to tiered, double-digit royalties on net sales, based on achieving certain developmental, regulatory, commercial and sales-based milestones.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines

Click here